EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) exon 20 insertions represent a significant subtype of non-small cell lung cancer mutations.
• These insertions often confer primary resistance to conventional EGFR tyrosine kinase inhibitors due to steric hindrance in the ATP-binding pocket.
• Over 100 distinct variants necessitate precise diagnostic and treatment strategies.

Purpose of the Study:

• To review the diagnostic challenges and therapeutic advancements for EGFR exon 20 insertion mutations in non-small cell lung cancer.
• To highlight the evolution of treatment strategies and identify areas for future research.

Main Methods:

• Review of current literature on EGFR exon 20 insertion mutations, diagnostic techniques, and therapeutic interventions.
• Analysis of clinical data regarding treatment efficacy, resistance mechanisms, and patient outcomes.

Main Results:

• Next-generation sequencing offers improved detection of actionable variants and co-alterations compared to PCR assays.
• Plasma-based ctDNA testing can be a useful adjunct but requires careful interpretation due to potential false negatives.
• New therapeutic strategies, including bispecific antibodies and next-generation TKIs, have emerged since 2021, improving outcomes but facing limited durability.

Conclusions:

• Accurate and comprehensive detection of EGFR exon 20 insertions is crucial for guiding treatment selection.
• While novel therapies offer progress, addressing resistance mechanisms, CNS penetration, and tumor heterogeneity is essential for improving long-term patient survival.
• Future research should focus on adaptive sequencing, combination therapies, and CNS-directed treatments.